Back to today’s briefing

Story perspectives

Eli Lilly's Drug Yields 28.7% Weight Loss, Reduces Knee Pain

12/11/2025

50 7 Full Breakdown

Summary

Story summary

Eli Lilly's experimental drug retatrutide produced 28.7% average weight loss (about 71 pounds) and a 75.8% reduction in knee pain in Phase 3 TRIUMPH-4 trial for obesity with knee osteoarthritis.
The trial involved 445 participants, of whom 84% had a body mass index of 35 or higher.
About 18% of participants on the highest dose discontinued due to side effects, including gastrointestinal issues, and further trials are expected in 2026.

1 of 1

Story summary

Eli Lilly's experimental drug retatrutide produced 28.7% average weight loss (about 71 pounds) and a 75.8% reduction in knee pain in Phase 3 TRIUMPH-4 trial for obesity with knee osteoarthritis.
The trial involved 445 participants, of whom 84% had a body mass index of 35 or higher.
About 18% of participants on the highest dose discontinued due to side effects, including gastrointestinal issues, and further trials are expected in 2026.